Accurate prediction of sudden cardiac death following heart attack is currently not feasible, say researchers
However, improved risk stratification across the whole LVEF range (patients with LVEF ≤ 35% and also patients with LVEF > 35% ...
pharmaphorum3y
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure
Despite advancements in treatment in multiple drug classes, mortality remains a significant issue and treatment options for a broader range of patients ... failure with LVEF over 40%, the once ...